SEGMENTS

3 Months Ended

Mar. 31, 2022

SEGMENTS [Abstract]

SEGMENTS

11. SEGMENTS

The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company’s ADMA BioManufacturing segment reflects the Company’s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1). The Plasma Collection Centers segment as of March 31, 2022 consists of ten plasma collection facilities in various stages of approval and development located throughout the U.S., five of which hold an approved license with the FDA. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables:

Three Months Ended March 31, 2022
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	25,728,625		$	3,338,760		$	35,708		$	29,103,093
Cost of product revenue		22,213,781			3,227,265			-			25,441,046
Loss from operations		(4,442,684	)		(3,863,094	)		(6,509,288	)		(14,815,066	)
Interest and other expense, net		(49,267	)		(729	)		(3,472,854	)		(3,522,850	)
Loss on extinguishment of debt		-			-			(6,669,941	)		(6,669,941	)
Net loss		(4,491,951	)		(3,863,823	)		(16,652,083	)		(25,007,857	)
Capital expenditures		1,310,379			1,531,706			-			2,842,085
Depreciation and amortization expense		1,111,951			477,503			763			1,590,217
Total assets		214,150,322			32,568,911			61,313,259			308,032,492

Three Months Ended March 31, 2021
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated
Revenues	$	13,421,043		$	2,591,867		$	35,708		$	16,048,618
Cost of product revenue		15,449,757			2,320,365			-			17,770,122
Loss from operations		(9,505,689	)		(1,970,841	)		(3,687,719	)		(15,164,249	)
Interest and other expense, net		(21,513	)		(384	)		(3,193,795	)		(3,215,692	)
Net loss		(9,527,202	)		(1,971,225	)		(6,881,514	)		(18,379,941	)
Capital expenditures		1,012,980			1,558,181			-			2,571,161
Depreciation and amortization expense		1,009,770			217,991			1,867			1,229,628
Total assets		156,535,177			17,397,612			61,734,239			235,667,028

Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:

	Three Months Ended March 31,
	2022		2021
United States	$	27,316,151	$	13,678,008
International		1,786,942		2,370,610
Total revenues	$	29,103,093	$	16,048,618